• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab.

作者信息

Hamacher Rainer, Kämpfe Dietrich, Reuter-Jessen Kirsten, Pöttgen Christoph, Podleska Lars E, Farzaliyev Farhad, Steinau Hans-Ulrich, Schuler Martin, Schildhaus Hans-Ulrich, Bauer Sebastian

机构信息

Rainer Hamacher, Martin Schuler, Sebastian Bauer, Christoph Pöttgen, Lars E. Podleska, Farhad Farzaliyev, and Hans-Ulrich Steinau, University Hospital Essen, University Duisburg-Essen; Martin Schuler and Sebastian Bauer, German Cancer Consortium, Partner Site University Hospital Essen, Essen; Dietrich Kämpfe, Hematology and Oncology Practice, Lüdenscheid; and Kirsten Reuter-Jessen and Hans-Ulrich Schildhaus, University Hospital Göttingen, Göttingen, Germany.

出版信息

JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.17.00107.

DOI:10.1200/PO.17.00107
PMID:35135124
Abstract
摘要

相似文献

1
Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab.头皮PD-L1阳性晚期血管肉瘤对帕博利珠单抗的显著反应
JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.17.00107.
2
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.帕博利珠单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期 HER2 阳性乳腺癌（PANACEA）：一项单臂、多中心、Ib-2 期试验。
Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.
3
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.帕博利珠单抗治疗晚期黑色素瘤或 PD-L1 阳性、晚期、复发、难治性实体瘤或淋巴瘤的儿科患者（KEYNOTE-051）：一项开放标签、单臂、1-2 期临床试验的中期分析。
Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4.
4
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.帕博利珠单抗作为程序性死亡受体配体1（PD-L1）阳性晚期非小细胞肺癌患者的一线治疗：一项1期试验。
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
5
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
6
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
7
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
8
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.帕博利珠单抗对比化疗用于未经治疗的、PD-L1 阳性的局部晚期或转移性非小细胞肺癌中国患者的随机临床研究：KEYNOTE-042 中国研究。
Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9.
9
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
10
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.FDA 批准概要：帕博利珠单抗用于表达 PD-L1 的复发性局部晚期或转移性胃或胃食管连接部腺癌。
Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17.

引用本文的文献

1
A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy.1例伴有真皮内转移的皮肤血管肉瘤对基于PD-1抑制的免疫疗法有反应。
JAAD Case Rep. 2025 Jul 9;64:67-70. doi: 10.1016/j.jdcr.2025.05.046. eCollection 2025 Oct.
2
PD-L1 expression assessment in Angiosarcoma improves with artificial intelligence support.在人工智能支持下，血管肉瘤中PD-L1表达评估得到改善。
J Pathol Inform. 2025 May 9;18:100447. doi: 10.1016/j.jpi.2025.100447. eCollection 2025 Aug.
3
Current understanding of angiosarcoma: disease biology and evolving treatment.
血管肉瘤的当前认识：疾病生物学与不断发展的治疗方法
Arch Craniofac Surg. 2023 Oct;24(5):203-210. doi: 10.7181/acfs.2023.00409. Epub 2023 Oct 20.
4
Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors.皮肤血管肉瘤：检查点抑制剂治疗的当前证据综述
Front Med (Lausanne). 2023 Mar 13;10:1090168. doi: 10.3389/fmed.2023.1090168. eCollection 2023.
5
Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups.免疫和基因组分析揭示血管肉瘤亚组之间的临床相关差异。
Cancers (Basel). 2022 Nov 30;14(23):5938. doi: 10.3390/cancers14235938.
6
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.在单中心治疗的一组血管肉瘤患者中，免疫检查点阻断治疗反应的临床、基因组和转录组相关性。
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004149.
7
Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.分析血管肉瘤发病机制亚组中的 PD-1、PD-L1 和 T 细胞浸润。
Immunol Res. 2022 Apr;70(2):256-268. doi: 10.1007/s12026-021-09259-4. Epub 2022 Jan 19.
8
Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology.局限性血管肉瘤，并非单一疾病：一项基于原发部位和病因的预后回顾性单中心研究
Sarcoma. 2021 Sep 10;2021:9960085. doi: 10.1155/2021/9960085. eCollection 2021.
9
Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report.免疫疗法在肺血管肉瘤中的作用：一例报告
Case Rep Oncol. 2021 Jun 9;14(2):797-801. doi: 10.1159/000516402. eCollection 2021 May-Aug.
10
[Cutaneous angiosarcoma clinically presenting as Quincke's edema].临床表现为昆克水肿的皮肤血管肉瘤
Hautarzt. 2021 Sep;72(9):801-804. doi: 10.1007/s00105-020-04748-3. Epub 2021 Jan 13.